

学術集会名 : 第 83 回日本循環器学会学術集会

会期/開催地 : 2019 年 3 月 29 日~31 日 横浜

セッション名 : シンポジウム 10

CCU で勤務するためにこれだけは知っておきたい集中治療の最新の話

座長 :

笠岡 俊志 (熊本大学 救急・総合診療部)

佐藤 直樹 (日本医科大学武蔵小杉病院 循環器科・集中治療室)

SY10-1

Short-Time Mechanical Circulatory Support Using Impella

[演者] 吉田 昇平:1

[共同演者] 戸田 宏一:1, 宮川 繁:1, 吉川 泰司:1, 秦 広樹:1, 島村 和男:1, 金 啓和:1, 吉岡 大輔:1, 甲斐沼 尚:1, 前田 孝一:1, 河村 拓史:1, 河村 愛:1, 政田 健太:1, 彦惣 俊吾:2, 溝手 勇:2, 世良 英子:2, 中本 敬:2, 坂田 泰史:2, 上野 高義:1, 倉谷 徹:1, 澤 芳樹:1  
1:大阪大学 心臓血管外科学, 2:大阪大学 循環器内科学

BACKGROUND:Refractory cardiogenic shock is a major therapeutic challenge. Short-term mechanical circulatory support has been used to improve the hemodynamics of patients with cardiogenic shock. The Impella capable of sufficient circulatory support and left ventricular chamber unloading with minimal invasion could be used in Japan on September 2017, but the effectiveness of Impella has not been reported in Japan.METHODSWe retrospectively investigated the hemodynamic change and the outcome in 11 patients with Impella used for cardiogenic shock.RESULTS:Impella 2.5 was used in 2 cases for 10 ± 4 days and Impella 5.0 was used in 9 cases for 17 ± 8 days. In 6 of 11 cases, Impella was used for the progression of pulmonary congestion during percutaneous cardiopulmonary system and intra-aortic balloon pumping support for myocardial infarction or fulminant myocarditis, resulting in disappearance of the pulmonary congestion in few days with 74 ± 4 % of SvO<sub>2</sub>. In the other 5 cases, Impella was used for acute deterioration on end-stage cardiomyopathy as a bridge to bridge or recovery, increasing cardiac output to 6.0 ± 0.5L/min and SvO<sub>2</sub> to 74 ± 5 %.CONCLUSION:The Impella provided sufficient circulatory support for cardiogenic shock. Although further experiences are needed, this new device may provide promising outcomes for acute heart failure.

[Keywords] shock / heart failure